SecBot SecBot
SECBOTREPLAY Home › Report › RVMD

RVMD · Revolution Medicines announced FDA approval of RASONQUE (daraxonrasib)…

Revolution Medicines, Inc. · 8-K filed Aug 26, 2026 at 13:33 ET

At the news

BULLISHIMPACT 8/10

8-K filed Aug 26, 2026 at 13:33 ET

Revolution Medicines announced FDA approval of RASONQUE (daraxonrasib) for metastatic pancreatic adenocarcinoma on August 26, 2026, based on Phase 3 RASolute 302 data. The oral therapy is now available in the U.S. with a wholesale acquisition cost of $39,800 per 30-day supply. This is a transformative milestone for the company, converting its lead pipeline asset to a commercial product in a large unmet-need indication.

  • FDA approved RASONQUE (daraxonrasib) for metastatic pancreatic adenocarcinoma after at least one prior systemic therapy or when multiagent therapy is not an option.
  • Approval based on Phase 3 RASolute 302 trial vs. investigator's choice chemotherapy.
  • Once-daily oral tablets immediately available for prescribing in the U.S.
  • Wholesale acquisition cost is $39,800 for a 30-day supply at the recommended dose.

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access